Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (4): 290-309     DOI: 10.3909/ricm0773
Review Previous articles | Next articles
The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia
Norman E. Lepor1, 2, Laurn Contreras2, Chirag Desai2, Dean J. Kereiakes3
1 The David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center, Los Angeles, CA
2 Westside Medical Associates of Los Angeles, Beverly Hills, CA
3 The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH
Download:  PDF(607KB)  ( 143 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in developed nations, and it is rising rapidly in other parts of the developing world. Levels of low-density lipoprotein cholesterol (LDL-C) are directly correlated with atherogenic risk, and statin-based therapy is the most common management for these patients. However, many patients exhibit resistance to and/or adverse effects from statin therapy, and there is a need for adjunctive therapies or statin alternatives for these patients. The recently discovered human protein proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in LDL-C metabolism. PCSK9 promotes LDL receptor (LDL-R) degradation with a consequent reduction in LDL-R density and an increase in LDL-C levels. Consequently, PCSK9 inhibition to reduce LDL-C levels has become a primary focus for drug development. Numerous clinical trials focusing on monoclonal antibodies against PCSK9 have demonstrated efficacy equal to or greater than statin therapy for lowering LDL-C levels. Long-term trials are underway to assess safety, tolerability, and ability to reduce ASCVD.
Key words:  Hypercholesterolemia      PCSK9      Low-density lipoprotein cholesterol      Atherosclerotic cardiovascular disease      Anti-PCSK9 monoclonal antibodies     
Published:  30 December 2014     

Cite this article: 

Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0773     OR     https://rcm.imrpress.com/EN/Y2014/V15/I4/290

[1] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[2] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[3] Jennifer G. Robinson, Karol E. Watson. Can We Cure Atherosclerosis?[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 20-24.
[4] Seth J. Baum, Alan S. Brown. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 25-30.
[5] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31-46.
[6] Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[7] Jane I. Won, Jun Zhang, Kristen M. Tecson , Peter A. McCullough. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 21-28.
[8] Seth J. Baum, Daniel Soffe, P. Barton Duell. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 16-27.
[9] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[10] Karol E. Watson, Eric H. Stocker, Douglas S. Jacoby, Peter A. McCullough. Advanced Lipid Testing: When, Why, and In Whom?[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 310-319.
[11] Divya Ratan Verma, Eliot A. Brinton. Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 86-101.
[12] Emil M. deGoma. Lomitapide for the Management of Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 109-118.
[13] Peter P. Toth, Prediman K. Shah, Michael J. Wilkinson, Michael H. Davidson, Peter A. McCullough. Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 1-10.
[14] Vasilios Papademetriou. Cardiovascular Protection Paradigms: Is Change on the Horizon?[J]. Reviews in Cardiovascular Medicine, 2007, 8(4): 200-213.
[15] Thomas M. Bashore, David P. Faxon, Norman E. Lepor, Prediman K. Shah, Karol E. Watson, Arthur E. Weyman. Best of the ACC 2007 Scientific Sessions[J]. Reviews in Cardiovascular Medicine, 2007, 8(2): 101-117.
No Suggested Reading articles found!